{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.0"},{"groupId":"OG001","value":"55.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"256"}],"units":"Participants"}],"description":"No. of patients who were clinical benefit responders over the no. of randomised patients x100. A clinical benefit responder = a patient whose best response is CR, PR or SD\\>=24 weeks (where a best response of SD = no new lesions and for existing lesions; neither suffient shrinkage to count as PR nor sufficient growth to count as progression)","groups":[{"description":"Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg","id":"OG000","title":"Fulvestrant + Anastrozole"},{"description":"Anastrozole 1 mg","id":"OG001","title":"Anastrozole"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009","title":"Percentage of Clinical Benefit Rate (CBR) Responders","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}